Geron Corp (GERN): Cutting PT From $6 To $5 - FBR

September 13, 2016 7:56 AM EDT
Get Alerts GERN Hot Sheet
Price: $2.11 -1.4%

Rating Summary:
    5 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 18 | New: 30
Trade GERN Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

FBR Capital analyst, Thomas Yip, reiterated his Outperform rating on shares of Geron Corporation (NASDAQ: GERN) but cut his price target to $5 from $6 based on amendments to the Phase II IMbark trial of imetelstat for the treatment of myelofibrosis (MF). The reduced PT is due to a higher clinical risk for imetelstat and a six-month delay of the projected approval for the MF indication (from late 2021 to mid-2022).

Despite the discontinued low dose arm (4.7 mg/kg), the analyst anticipates IMbark to go on with high dose imetelstat (9.4 mg/kg) without delay.

For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here.

Shares of Geron Corporation closed at $2.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Add Your Comment